Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate.

Article Details

Citation
Copy to clipboard

Shen Z, Wang Y, Xu H, Zhang Q, Sha C, Sun B, Li Q

Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate.

Int J Biol Macromol. 2021 Jun 1;180:494-509. doi: 10.1016/j.ijbiomac.2021.03.020. Epub 2021 Mar 6.

PubMed ID
33684428 [ View in PubMed
]
Abstract

Ziv-aflibercept (aflibercept) is a recombinant fusion protein which combines the portions of human vascular endothelial growth factor receptors extracellular domains fused to the Fc portion of human IgG1. It is a highly sialylated glycoprotein with 5 N-glycosylation sites. In this study, a comprehensive strategy for comparability study of the complex glycosylation was developed between aflibercept and the biosimilar candidate including the investigations on N-glycosylation sites, site occupancy, site-specific glycoforms, released glycans and sialic acids. The results indicated that same N-glycosylation sites were identified, site occupancy were 100% except N(68) site, site-specific glycoforms and released glycans showed similar glycan species, contents of NANA were at a same level for two products. Minor differences were found between two products. The biosimilar candidate presented lower level of aglycosylation, lower level of glycans containing one terminal sialic acid, higher level of glycans containing two terminal sialic acids, higher level of G0F and Man5, lower level of G1F and G2F compared with aflibercept. However, further studies exhibited no differences were observed in the cell-based biological potency and Fc effector function. Moreover, the biosimilar candidate showed a similar pharmacokinetics curve and bioequivalence compared with aflibercept.

DrugBank Data that Cites this Article

Drugs